Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Condition:   Acral Melanoma Intervention:   Drug: SHR-1210+Apatinib Sponsor:   Di Wu Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials